FDA approves additional formulation of biosimilar FDA approves additional formulation of biosimilar US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.
New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes
US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes